Literature DB >> 7684993

Results of a prospective randomized trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of the cervix.

J Sardi1, C Sananes, A Giaroli, J Bayo, N G Rueda, S Vighi, N Guardado, G Paniceres, L Snaidas, C Vico.   

Abstract

A prospective randomized trial was carried out in patients with squamous carcinoma of the cervix uteri, stage Ib bulky. The protocol considers two arms: the control group (75 patients) and the neoadjuvant one (76 patients). All the patients were classified according to the FIGO staging system and in order to determine the tumor size objectively, an ultrasound scanning was done. After this a Wertheim-Meigs operation followed by adjuvant whole-pelvis irradiation was performed. In the neoadjuvant group the same procedures were carried out but three courses of chemotherapy with the "quick" VBP scheme were given before the treatment. The new therapeutic strategy proved to be very useful in bulky tumors in which the clinical examination showed a cervix increased in size and the ultrasound scanning a volume larger than 60 c.c. (> 4 x 4 x 4 cm). In those cases statistically significant differences were found between both groups when free disease interval and survival were considered. These were due to the fact that operability has been improved and the parametrial extension has been decreased as well as other risk factors such as vascular embolism, lymph node involvement, tumor-cervix quotient, and tumor volume. The use of this new strategy is not justified in small tumors (< 3-4 cm in diameter) because in those cases, survival is not improved with neoadjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684993     DOI: 10.1006/gyno.1993.1100

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

1.  The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma.

Authors:  Xiao-Dong Cheng; Wei-Guo Lu; Feng Ye; Xiao-Yun Wan; Xing Xie
Journal:  J Exp Clin Cancer Res       Date:  2009-06-29

2.  Survival benefits of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy in locally advanced chemoresistant cervical cancer.

Authors:  Youn Seok Choi; Jeong-Im Sin; Ju Hyun Kim; Gi Won Ye; Im Hee Shin; Tae Sung Lee
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

3.  Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study.

Authors:  Roberto Angioli; Francesco Plotti; Daniela Luvero; Alessia Aloisi; Federica Guzzo; Stella Capriglione; Corrado Terranova; Carlo De Cicco Nardone; Pierluigi Benedetti-Panici
Journal:  Tumour Biol       Date:  2014-03

4.  Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage IB2-IIA bulky cervical cancer.

Authors:  Yun-Hyun Cho; Dae-Yeon Kim; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2009-03-31       Impact factor: 4.401

5.  Experience in stage IB2 cervical cancer and review of treatment.

Authors:  Taner Turan; Burcu Aykan Yıldırım; Gökhan Tulunay; Nurettin Boran; Ferah Yıldız; Mehmet Faruk Köse
Journal:  J Turk Ger Gynecol Assoc       Date:  2010-03-01

6.  Prognostic risk model development and prospective validation among patients with cervical cancer stage IB2 to IIB submitted to neoadjuvant chemotherapy.

Authors:  Kecheng Huang; Haiying Sun; Xiong Li; Ting Hu; Ru Yang; ShaoShuai Wang; Yao Jia; Zhilan Chen; Fangxu Tang; Jian Shen; Xiaomin Qin; Hang Zhou; Runfeng Yang; Juan Gui; Lin Wang; Xiaolin Zhao; Jincheng Zhang; Jiong Liu; Lili Guo; Shuang Li; Shixuan Wang
Journal:  Sci Rep       Date:  2016-06-09       Impact factor: 4.379

7.  Optimal pathological response indicated better long-term outcome among patients with stage IB2 to IIB cervical cancer submitted to neoadjuvant chemotherapy.

Authors:  Kecheng Huang; Haiying Sun; Zhilan Chen; Xiong Li; ShaoShuai Wang; Xiaolin Zhao; Fangxu Tang; Yao Jia; Ting Hu; Xiaofang Du; Haoran Wang; Zhiyong Lu; Jia Huang; Juan Gui; Xiaoli Wang; Shasha Zhou; Lin Wang; Jincheng Zhang; Lili Guo; Ru Yang; Jian Shen; Qinghua Zhang; Shuang Li; Shixuan Wang
Journal:  Sci Rep       Date:  2016-06-21       Impact factor: 4.379

8.  Early response to neoadjuvant chemotherapy can help predict long-term survival in patients with cervical cancer.

Authors:  Xiong Li; Kecheng Huang; Qinghua Zhang; Jian Shen; Hang Zhou; Runfeng Yang; Lin Wang; Jiong Liu; Jincheng Zhang; Haiying Sun; Yao Jia; Xiaofang Du; Haoran Wang; Song Deng; Ting Ding; Jingjing Jiang; Yunping Lu; Shuang Li; Shixuan Wang; Ding Ma
Journal:  Oncotarget       Date:  2016-12-27

9.  Effect of neoadjuvant chemotherapy followed by surgery for FIGO stage I-II cervical cancer: a meta-analysis.

Authors:  Shu-Li Yang; Ling Chen; Yue He; Hui Zhao; Yu-Mei Wu
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.